Prognostic Analysis of NLR, PLR, and, LMR in Osteosarcoma at Dr. Wahidin Sudirohusodo Hospital

Authors

  • Febriani Helda Pongbala Department of Clinical Pathology, Faculty of Medicine, Hasanuddin University/Dr. Wahidin Sudirohusodo Hospital, Makassar
  • Uleng Bahrun Department of Clinical Pathology, Faculty of Medicine, Hasanuddin University/Dr. Wahidin Sudirohusodo Hospital, Makassar
  • Mansyur Arif Department of Clinical Pathology, Faculty of Medicine, Hasanuddin University/Dr. Wahidin Sudirohusodo Hospital, Makassar

DOI:

https://doi.org/10.24293/ijcpml.v30i2.2126

Keywords:

NLR, PLR, LMR, osteosarcoma

Abstract

Osteosarcoma is a primary pediatric bone malignancy with an annual incidence of 5.6 cases per million children under the age of 15. The high mortality rate leads to necessary for prognostic biomarkers of the disease. NLR, PLR, and LMR can be considered as prognostic predictors of osteosarcoma patients. This study aimed to determine the difference and correlation between NLR, PLR, and LMR based on grade and outcome in osteosarcoma patients. The study used medical record data from 122 osteosarcoma patients at Dr. Wahidin Sudirohusodo Hospital, Makassar. Samples were grouped by stage according to Enneking criteria (Grade I, II, and III) and by outcome (deceased and not deceased), then analyzed based on NLR, PLR, and LMR values using the Kruskal-Wallis test and the Mann-Whitney test (significant if p<0.05). There was a significant difference in NLR, PLR, and LMR values by grade, (p=0.05). There was a significant difference in the value of NLR, and LMR based on output (p=0.00), but not in PLR (p=0.954). There was a correlation between the values of NLR, PLR, and LMR and the stage of osteosarcoma (p=0.05). Based on the outcome, a correlation with the NLR and LMR values was obtained (p=0.00), but there was no correlation with the PLR value (p=0.955). Cut-off NLR, PLR, and LMR were 4.43; 0.21; and 0.44, respectively, with sensitivity of 76%, 56%, and 76% and a specificity of 76%, 63.9%, and 68%, respectively. There were differences in NLR, PLR, and LMR values based on the stage and outcome of osteosarcoma.  Higher NLR, PLR, and LMR values will lead to a higher stage of osteosarcoma and a worse outcome. Cut-off NLR, PLR, and LMR optimal for distinguishing stage of osteosarcoma were 4.43; 0.21, and 0.44, respectively.

Downloads

Download data is not yet available.

References

Lindsey BA, Markel JE, Kleinerman ES. Osteosarcoma overview. Rheumatol Ther, 2017; 4(1): 25–43.

Misaghi A, Goldin A, Awad M, Kulidjian AA. Osteosarcoma: A comprehensive review. SICOT J, 2018; 4: 12.

Jiang ZY, Liu JB, Wang XF, Ma YS, Fu D. Current status and prospects of clinical treatment of osteosarcoma. SAGE, 2022; 21: 1-12. Available from: https://10.1177/15330338221124696 (accessed May 3, 2022).

Faisham WI, Saad AZM, Alsaigh LN, Azman MZN, Imran MK, et al. Prognostic factors and survival rate of osteosarcoma: A single-institution study. Asia. Pac. J. Clin. Oncol, 2017; 13(2): e104–e110.

Xin S, Wei G. Prognostic factors in osteosarcoma: A study level meta-analysis and systematic review of current practice. J. Bone Oncol, 2020; 21: 100281.

Kamal A, Prasetyo R. Association between laboratory markers and oncological outcomes in patients with osteosarcoma-A review of osteosarcoma treatment in Indonesia. Formos. J. Surg, 2018; 51(3): 111–117.

Xia WK, Liu ZL, Shen D, Lin QF, Su J, Mao WD. Prognostic performance of pre-treatment NLR and PLR in patients suffering from osteosarcoma. World J. Surg. Oncol, 2016; 14(1): 1–8.

Liu T, Fang XC, Ding Z, Sun ZG, Sun LM, Wang YL. Pre-operative lymphocyte-to-monocyte ratio as a predictor of overall survival in patients suffering from osteosarcoma. FEBS Open Bio, 2015; 5: 682–687.

Mehlman CT, Cripe TP, Talavera F, Binitie O. Pedoman osteosarkoma. Medscape, 2022; 1-4. Available from: https:// emedicine.medscape.com/ article/ 1256857-guideline#g3 (accessed May 3, 2022).

Kim C, Davis LE, Albert CM, Samuels B, Roberts JL, Wagner MJ. Osteosarcoma in pediatric and adult populations: Are adults just big kids?. MDPI, 2023; 15(20): 5044. Available from: http:// 10.3390/cancers15205044 (accessed May 3, 2023).

Song X, Zhang H, Yin F, Guo P, Yang X, et al. Review article systemic inflammatory markers for predicting overall survival in patients with osteosarcoma: A systematic review and meta-analysis. PMC, 2021; 21: 1-16. Available from: https:// doi.org/ 10.1155/2021/3456629 (accessed May 3, 2022).

Leoncini E, Ricciardi W, Cadoni G, Arzani D, Petrelli L, et al. Adult height and head and neck cancer: A pooled analysis within the INHANCE consortium. Springer, 2023; 36(10): 1391-2014. Available from: https:// 10.1007/s10654-013-9863-2 (accessed May 3, 2023).

Yapar A, Tokgoz MA, Yapar D, Atalay IB, Ulucaköy C, Gungor BS. Diagnostic and prognostic role of neutrophil/lymphocyte ratio, platelet/lymphocyte ratio, and lymphocyte/monocyte ratio in patients with osteosarcoma. Jt. Dis. Relat. Surg, 2021; 32(2): 489–496.

Corrales L, Matson V, Flood B, Spranger S, Gajewski TF. Innate immune signaling and regulation in cancer immunotherapy. Cell Research, 2017; 27: 96-108. Available from: https:// 10.1038/cr.2016.149 (accessed May 3, 2023).

Peng LP, Li J, Li XF. Prognostic value of neutrophil/lymphocyte, platelet/lymphocyte, lymphocyte/monocyte ratios and glasgow prognostic score in osteosarcoma: A meta-analysis. World J. Clin. Cases, 2022; 10(7): 2194–2205.

Downloads

Submitted

2023-04-28

Published

2024-02-16

How to Cite

[1]
Pongbala, F.H., Bahrun, U. and Arif, M. 2024. Prognostic Analysis of NLR, PLR, and, LMR in Osteosarcoma at Dr. Wahidin Sudirohusodo Hospital. INDONESIAN JOURNAL OF CLINICAL PATHOLOGY AND MEDICAL LABORATORY. 30, 2 (Feb. 2024), 172–176. DOI:https://doi.org/10.24293/ijcpml.v30i2.2126.

Issue

Section

Articles